U.S. markets open in 49 minutes

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.3900-0.1600 (-10.32%)
At close: 4:00PM EDT

1.4400 +0.05 (3.60%)
Pre-Market: 8:02AM EDT

Sign in to post a message.
  • S
    SLass
    Evoke Pharma has filed an 8k as to the previous voting: https://evokepharmainc.gcs-web.com/static-files/298b1b06-1486-4c7a-840a-a4c6064ea78d

    The float will remain the same, the increase was denied.

    "• The approval of the amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorizednumber of shares of common stock from 50,000,000 to 100,000,000

    Shares Voted For 12,090,384 Against 6,617,972 Abstain 37,319

    There were no broker non-votes related to the amendment to the Company’s Amended and Restated Certificate of Incorporation.

    Although the forgoing proposal received a substantial majority of votes cast at the Annual Meeting. g, it did not receive a majority of the outstanding shares of common stock as required and consequently was not approved."
  • S
    Steve Stevens
    wonder if goyner's trying to set a new record for lowest market cap for a co. with an fda-approved drug.
  • N
    Nahla
    average estimate for Q1 revenue is 850k and for Q4 2020 it was 0. It would be nice to see it around that mark and start an upward trend already. Do they really need a conference if revenue is good?
  • r
    rambo
    Nice of them to share the reporting date, eh? After the market closes, probably for the best this time,
  • p
    peter
    anyone know the result of the meeting?
  • s
    sam
    “The time of maximum pessimism is the best time to buy and the time of maximum optimism is the best time to sell”.
    Bullish
  • S
    SLass
    I am long on this stock, but can't believe the lack of earnings guidance. I am sure management is getting ready for tomorrow's meeting, but this is brutal.
  • B
    B
    Best jumping in spot will be during the big dip after earnings. Gonyer keeps it up and he may be able to lower share count with a RS!
  • s
    sam
    Orin Hirachman reloaded and more will follow
    Bullish
  • p
    peter
    selllllll the company already! to a bigger and better company to do this drug justice
  • P
    Paul
    @B - what's an RS please?
  • p
    peter
    Dave Gonyer said in the YouTube video that "once you have the product and have a sales team out there, people start calling you and we're always open to opportunities" not the exact wording. but I would think that he's saying that companies did call about opportunities to maybe buy them out and they're open to it. just my 2 cent
  • s
    sam
    Since The float will remain the same, the increase is denied and the earnings are better than last time, it will bounce back to $3 plus before earning so easy double from here. Just added some more.
    Bullish
  • p
    peter
    can someone credible tell us if we dodged the bullet today? with the dilution
  • d
    dude
    Look at $abbv breaking out to the upside and $amgn moving back up. Will bring a lot of small players along too after brutal last few months in biotech pharma. Want to see more M&A also, that’s what we need as tech money shifts to healthcare.
  • p
    peter
    evoke, please surprise me tmr with some good news......
  • d
    dude
    The pandemic is a real impact on pharma, look at Amgen and their report yesterday. So it’s easy to understand why launch of Gimoti is proving more difficult than anticipated, but we will have significant sales by end of the year as US returns to more normalcy.

    Remember every 1000 patients is $10 million in revenue, that’s huge opportunity! 15 patients 4Q20, 100 patients 1Q21, 300 patients 2Q21, 700 patients 3Q21, over 1000 by 4Q21 and from there we have liftoff🚀🚀🚀🚀

    January we learned over 75% of doctors intend to prescribe from market research of 100 docs, Feb we learned that revenue could be in the $100 million range by seeking alpha analysis, March we learned there’s over 100 prescribers and numbers growing every day. March we also learned that ramp up is tough and slow and here we are with a market cap 3-4x below where we will be by year end. Also shorts have piled on over 1 million shares to cover. Load up and crush the shorts!
  • p
    peter
    the meeting is today right? team evoke
  • S
    Sammy Z
    Gimoti is starting to sell as Covid becomes a way of living right now. More and more doctors have been contact and are starting to right prescriptions. We should receive news, that more insurance companies will cover costs of Gimoti. The stock is way undervalued for a approved drug, even if they got a slow start out of the gate.
    Bullish
  • M
    Matt
    Probably a couple of weeks now until Q1 Results. I'm bored, so I am going to stick my neck out and predict $200K sales in Q1. That would demonstrate good progress, while still low volume. Cue Elvis